Clinical Trials Browser

Interventional × Nasopharyngeal Carcinoma × fludarabine × Clear all

NCT02065362 2026-01-29

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Phase 1 Active not recruiting

Nasopharyngeal Carcinoma, Camurati-Engelmann Syndrome

NCT02287311 2025-02-24

MABEL

Phase 1 Active not recruiting

38 enrolled 16 charts

Head & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Smooth Muscle Tumor

NCT05654077 2022-12-19

EBV CAR-T Cells for Nasopharyngeal Carcinoma

Phase EARLY_PHASE1 Unknown

Nasopharyngeal Carcinoma

NCT05616468 2022-12-15

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Phase EARLY_PHASE1 Unknown

Nasopharyngeal Carcinoma

NCT03648697 2020-08-11

EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT03044743 2017-05-02

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

Phase 1/2 Unknown

GastrointestinalHead & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Stomach Neoplasms, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse